<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34193068</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Increased cerebrospinal fluid adenosine 5'-triphosphate in patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>255</StartPage><MedlinePgn>255</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-021-02288-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extracellular adenosine 5'-triphosphate (ATP) has been suggested to cause neuroinflammation and motor neuron degeneration by activating microglia and astrocytes in amyotrophic lateral sclerosis (ALS). Since we have developed a highly sensitive ATP assay system, we examined cerebrospinal fluid (CSF) ATP levels in patients with ALS whether it can be a useful biomarker in ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-eight CSF samples from 44 patients with ALS were assayed for ATP with a newly established, highly sensitive assay system using luciferase luminous reaction. CSF samples from patients with idiopathic normal pressure hydrocephalus (iNPH) were assayed as a control. Patients were divided into two groups depending on their disease severity, as evaluated using the Medical Research Council (MRC) sum score. Correlations between the CSF ATP levels and other factors, including clinical data and serum creatinine levels, were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSF ATP levels were significantly higher in patients with ALS than in the iNPH (716&#x2009;&#xb1;&#x2009;411 vs. 3635&#x2009;&#xb1;&#x2009;5465&#xa0;pmol/L, p&#x2009;&lt;&#x2009;0.01). CSF ATP levels were significantly higher in the more severe group than in the iNPH group (6860&#x2009;&#xb1;&#x2009;8312 vs. 716&#x2009;&#xb1;&#x2009;411&#xa0;pmol/L, p&#x2009;&lt;&#x2009;0.05) and mild group (6860&#x2009;&#xb1;&#x2009;8312 vs. 2676&#x2009;&#xb1;&#x2009;3959&#xa0;pmol/L, p&#x2009;&lt;&#x2009;0.05) respectively. ALS functional rating scale-revised (ALSFRS-R) (37.9&#x2009;&#xb1;&#x2009;5.7 vs. 42.4&#x2009;&#xb1;&#x2009;2.8, p&#x2009;&lt;&#x2009;0.01) and serum creatinine levels (0.51&#x2009;&#xb1;&#x2009;0.13 vs. 0.68&#x2009;&#xb1;&#x2009;0.23&#xa0;mg/dL, p&#x2009;&lt;&#x2009;0.05) were significantly lower in the severe group than in the mild group respectively. A negative correlation of CSF ATP levels with MRC sum score was demonstrated in the correlation analysis adjusted for age and sex (r&#x2009;=&#x2009;-0.3, p&#x2009;=&#x2009;0.08).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extracellular ATP is particularly increased in the CSF of patients with advanced ALS. CSF ATP levels may be a useful biomarker for evaluating disease severity in patients with ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nukui</LastName><ForeName>Takamasa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niimi</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Data Science, Graduate School of Data Science, University of Shiga, 1-1-1 Banba Hikone, Shiga, 522-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dougu</LastName><ForeName>Nobuhiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konishi</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anada</LastName><ForeName>Ryoko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Noriyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitajima</LastName><ForeName>Isao</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatsuji</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. nakatsuj@med.u-toyama.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ATP</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Cerebrospinal fluid</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34193068</ArticleId><ArticleId IdType="pmc">PMC8243489</ArticleId><ArticleId IdType="doi">10.1186/s12883-021-02288-4</ArticleId><ArticleId IdType="pii">10.1186/s12883-021-02288-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262(Pt B):111&#x2013;20. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Corcia P, MadjiHounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015;22(10):1385&#x2013;1390. doi: 10.1111/ene.12754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12754</ArticleId><ArticleId IdType="pubmed">26095828</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(2):156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285(1&#x2013;2):95&#x2013;99. doi: 10.1016/j.jns.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2009.06.002</ArticleId><ArticleId IdType="pubmed">19552925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, et al. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6(12):2489&#x2013;2502. doi: 10.1002/acn3.50943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50943</ArticleId><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710. 10.1016/j.neulet.2017.06.052.</Citation></Reference><Reference><Citation>Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009;32(1):19&#x2013;29. doi: 10.1016/j.tins.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.10.001</ArticleId><ArticleId IdType="pubmed">19008000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HG, Won SM, Gwag BJ, Lee YB. Microglial P2X(7) receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer&amp;apos;s disease. Exp Mol Med. 2011;43(1):7&#x2013;14. doi: 10.3858/emm.2011.43.1.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3858/emm.2011.43.1.001</ArticleId><ArticleId IdType="pmc">PMC3041940</ArticleId><ArticleId IdType="pubmed">21088470</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Hernandez JI, Gomez-Villafuertes R, Leon-Otegui M, Hontecillas-Prieto L, Del Puerto A, Trejo JL, et al. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer&amp;apos;s disease through GSK3beta and secretases. Neurobiol Aging. 2012;33(8):1816&#x2013;1828. doi: 10.1016/j.neurobiolaging.2011.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.040</ArticleId><ArticleId IdType="pubmed">22048123</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcellino D, Suarez-Boomgaard D, Sanchez-Reina MD, Aguirre JA, Yoshitake T, Yoshitake S, et al. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson&amp;apos;s disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm (Vienna) 2010;117(6):681&#x2013;687. doi: 10.1007/s00702-010-0400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0400-0</ArticleId><ArticleId IdType="pubmed">20387084</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmo MR, Menezes AP, Nunes AC, Pliassova A, Rolo AP, Palmeira CM, et al. The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis. Neuropharmacology. 2014;81:142&#x2013;152. doi: 10.1016/j.neuropharm.2014.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.01.045</ArticleId><ArticleId IdType="pubmed">24508709</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007;27(35):9525&#x2013;9533. doi: 10.1523/jneurosci.0579-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0579-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673129</ArticleId><ArticleId IdType="pubmed">17728465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, Bongarzone ER, et al. P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation. 2008;5:33. doi: 10.1186/1742-2094-5-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-33</ArticleId><ArticleId IdType="pmc">PMC2518548</ArticleId><ArticleId IdType="pubmed">18691411</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosi N, Finocchi P, Apolloni S, Cozzolino M, Ferri A, Padovano V, et al. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol. 2009;183(7):4648&#x2013;56. 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cieslak M, Roszek K, Wujak M. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2019;15(1):1&#x2013;15. doi: 10.1007/s11302-018-9633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-018-9633-4</ArticleId><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Nukui T, Matsui A, Niimi H, Yamamoto M, Matsuda N, Piao JL, et al. Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS) Mitochondrion. 2020;50:145&#x2013;148. doi: 10.1016/j.mito.2019.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2019.11.001</ArticleId><ArticleId IdType="pubmed">31756516</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Ozono Y, Mikuriya S, Kohro Y, Tozaki-Saitoh H, Iwatsuki K, et al. Dorsal horn neurons release extracellular ATP in a VNUT-dependent manner that underlies neuropathic pain. Nat Commun. 2016;7:12529. doi: 10.1038/ncomms12529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12529</ArticleId><ArticleId IdType="pmc">PMC4990655</ArticleId><ArticleId IdType="pubmed">27515581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans G, Clerckx B, Vanhullebusch T, Segers J, Vanpee G, Robbeets C, et al. Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle Nerve. 2012;45(1):18&#x2013;25. doi: 10.1002/mus.22219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22219</ArticleId><ArticleId IdType="pubmed">22190301</ArticleId></ArticleIdList></Reference><Reference><Citation>Okanojo M, Miyashita N, Tazaki A, Tada H, Hamazoto F, Hisamatsu M, et al. Attomol-level ATP bioluminometer for detecting single bacterium. Luminescence. 2017;32(5):751&#x2013;756. doi: 10.1002/bio.3246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bio.3246</ArticleId><ArticleId IdType="pubmed">27958680</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7(7):575&#x2013;590. doi: 10.1038/nrd2605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2605</ArticleId><ArticleId IdType="pubmed">18591979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratov Y, Lalo U, Verkhratsky A, North RA. Vesicular release of ATP at central synapses. Pflugers Arch. 2006;452(5):589&#x2013;597. doi: 10.1007/s00424-006-0061-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-006-0061-x</ArticleId><ArticleId IdType="pubmed">16639550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Chen G, Zhou W, Song A, Xu T, Luo Q, et al. Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol. 2007;9(8):945&#x2013;953. doi: 10.1038/ncb1620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1620</ArticleId><ArticleId IdType="pubmed">17618272</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004;240:31&#x2013;304. doi: 10.1016/s0074-7696(04)40002-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0074-7696(04)40002-3</ArticleId><ArticleId IdType="pubmed">15548415</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A. Glia: the fulcrum of brain diseases. Cell Death Differ. 2007;14(7):1324&#x2013;1335. doi: 10.1038/sj.cdd.4402144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402144</ArticleId><ArticleId IdType="pubmed">17431421</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:33. doi: 10.1186/1742-2094-7-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-33</ArticleId><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori CF, Brambilla L, Martorana F, Rossi D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci. 2014;71(2):287&#x2013;297. doi: 10.1007/s00018-013-1429-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1429-7</ArticleId><ArticleId IdType="pubmed">23912896</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77(4):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664586</ArticleId><ArticleId IdType="pubmed">26663933</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeppsson A, Wikkels&#xf6; C, Blennow K, Zetterberg H, Constantinescu R, Remes AM, et al. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. J Neurol Neurosurg Psychiatry. 2019;90(10):1117&#x2013;1123. doi: 10.1136/jnnp-2019-320826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320826</ArticleId><ArticleId IdType="pmc">PMC6817981</ArticleId><ArticleId IdType="pubmed">31167811</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Garofalo DC, Santella RM, Sorenson EJ, Oskarsson B, Fernandes JAM, Jr., et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020:1&#x2013;10; doi: 10.1080/21678421.2020.1746810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373369</ArticleId><ArticleId IdType="pubmed">32276554</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Xu Y, Hu B, Wang J, Pan R, Murugan M, et al. Extracellular ATP enhances radiation-induced brain injury through microglial activation and paracrine signaling via P2X7 receptor. Brain Behav Immun. 2015;50:87&#x2013;100. doi: 10.1016/j.bbi.2015.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.06.020</ArticleId><ArticleId IdType="pubmed">26122280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291&#x2013;304. doi: 10.1111/nan.12511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104&#x2013;112. doi: 10.1179/1351000215y.0000000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215y.0000000026</ArticleId><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, et al. Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018;57(3):430&#x2013;434. doi: 10.1002/mus.25950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25950</ArticleId><ArticleId IdType="pmc">PMC5812805</ArticleId><ArticleId IdType="pubmed">28857199</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C, Calzaferri F, Garc&#xed;a AG. P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2020;13:93. doi: 10.3389/fnmol.2020.00093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00093</ArticleId><ArticleId IdType="pmc">PMC7303288</ArticleId><ArticleId IdType="pubmed">32595451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>